📣 VC round data is live. Check it out!
- Public Comps
- Solid Biosciences
Solid Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Solid Biosciences and similar public comparables like Zentiva, Astria Therapeutics, Lexicon Pharmaceuticals, Vor Biopharma and more.
Solid Biosciences Overview
About Solid Biosciences
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Founded
2013
HQ

Employees
100
Website
Financials (LTM)
EV
$545M
Valuation Multiples
Start free trialSolid Biosciences Financials
Solid Biosciences reported last 12-month revenue of — and negative EBITDA of ($193M).
In the same LTM period, Solid Biosciences generated — in gross profit, ($193M) in EBITDA losses, and had net loss of ($184M).
Revenue (LTM)
Solid Biosciences P&L
In the most recent fiscal year, Solid Biosciences reported revenue of — and EBITDA of ($178M).
Solid Biosciences is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.
Financial data powered by Morningstar, Inc.
Solid Biosciences Stock Performance
Solid Biosciences has current market cap of $712M, and enterprise value of $545M.
Market Cap Evolution
Solid Biosciences' stock price is $7.23.
Solid Biosciences share price decreased by 0.4% in the last 30 days, and increased by 125.2% in the last year.
Solid Biosciences has an EPS (earnings per share) of $-1.77.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $545M | $712M | 1.4% | -0.4% | 16.4% | 125.2% | $-1.77 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSolid Biosciences Valuation Multiples
Solid Biosciences trades at (2.8x) EV/EBITDA.
EV / Revenue (LTM)
Solid Biosciences Financial Valuation Multiples
As of May 5, 2026, Solid Biosciences has market cap of $712M and EV of $545M.
Solid Biosciences has a P/E ratio of (3.9x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Solid Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Solid Biosciences Margins & Growth Rates
Solid Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Solid Biosciences Operational KPIs
Solid Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.8M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Solid Biosciences Competitors
Solid Biosciences competitors include Zentiva, Astria Therapeutics, Lexicon Pharmaceuticals, Vor Biopharma, Arvinas, Alkaloid, Bioage Labs, BridgeBio Oncology, Guizhou Sanli and Ironwood Pharmaceuticals.
Most Solid Biosciences public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 2.8x | — | 9.8x | — | |||
| — | — | — | — | |||
| 13.6x | 15.2x | (16.3x) | (12.0x) | |||
| — | — | (0.7x) | (0.9x) | |||
| 0.1x | 0.1x | (0.2x) | (0.1x) | |||
| 2.0x | — | 19.3x | — | |||
| 51.3x | 61.7x | (5.8x) | (4.5x) | |||
| — | — | (1.8x) | (1.6x) | |||
This data is available for Pro users. Sign up to see all Solid Biosciences competitors and their valuation data. Start Free Trial | ||||||
Solid Biosciences Funding History
Before going public, Solid Biosciences raised $93M in total equity funding, across 2 rounds.
Solid Biosciences Funding Rounds
Solid Biosciences M&A Activity
Solid Biosciences has acquired 1 company to date.
Last acquisition by Solid Biosciences was on September 30th 2022. Solid Biosciences acquired AavantiBio for $75M (EV/Revenue multiple of ).
Latest Acquisitions by Solid Biosciences
| Description | AavantiBio is a Waltham, Massachusetts-based biopharmaceutical company advancing AAV gene therapies and editing technologies for central nervous system disorders like frontotemporal dementia and rare epilepsies. It focuses on delivering oversized transgenes via proprietary capsids. |
| HQ Country | |
| HQ City | — |
| Deal Date | 30 Sep 2022 |
| Valuation | $75M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Solid Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Solid Biosciences
| When was Solid Biosciences founded? | Solid Biosciences was founded in 2013. |
| Where is Solid Biosciences headquartered? | Solid Biosciences is headquartered in United States. |
| How many employees does Solid Biosciences have? | As of today, Solid Biosciences has over 100 employees. |
| Who is the CEO of Solid Biosciences? | Solid Biosciences' CEO is Alexander G. Cumbo. |
| Is Solid Biosciences publicly listed? | Yes, Solid Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Solid Biosciences? | Solid Biosciences trades under SLDB ticker. |
| When did Solid Biosciences go public? | Solid Biosciences went public in 2018. |
| Who are competitors of Solid Biosciences? | Solid Biosciences main competitors include Zentiva, Astria Therapeutics, Lexicon Pharmaceuticals, Vor Biopharma, Arvinas, Alkaloid, Bioage Labs, BridgeBio Oncology, Guizhou Sanli, Ironwood Pharmaceuticals. |
| What is the current market cap of Solid Biosciences? | Solid Biosciences' current market cap is $712M. |
| Is Solid Biosciences profitable? | No, Solid Biosciences is not profitable. |
| What is the current EBITDA of Solid Biosciences? | Solid Biosciences has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Solid Biosciences? | Current EBITDA multiple of Solid Biosciences is (2.8x). |
| What is the current FCF of Solid Biosciences? | Solid Biosciences' last 12 months FCF is ($98M). |
| What is the current EV/FCF multiple of Solid Biosciences? | Current FCF multiple of Solid Biosciences is (5.6x). |
| How many companies Solid Biosciences has acquired to date? | As of May 2026, Solid Biosciences has acquired 1 company. |
| What was the largest acquisition by Solid Biosciences? | $75M acquisition of AavantiBio on 30th September 2022 was the largest M&A Solid Biosciences has done to date. |
| What companies Solid Biosciences acquired? | Solid Biosciences acquired AavantiBio. |
| In how many companies Solid Biosciences has invested to date? | Solid Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Solid Biosciences
Lists including Solid Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
